İdIl Unal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
İdIl Unal has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ayda Acar
Ege University Medical Faculty, Department of Dermatology and Venereology, Izmir
7 shared publications - Ilgen Ertam
Department of Dermatology and Venereology Faculty of Medicine, Ege University Izmir Türkiye
6 shared publications - Banu Yaman
Department of Pathology, Ege University Faculty of Medicine, Izmir, Turkey
2 shared publications - Bengu Gerceker Turk
Special office, İzmir
2 shared publications - Can Ceylan
Department of Dermatology, Faculty of Medicine, Ege University
2 shared publications - Gunseli Ozturk
Department of Dermatology, Ege University Faculty of Medicine, Izmir, Turkey
2 shared publications
Latest Publications
- 25 October 2026
- Published by Wiley in The Journal of Dermatology
Hypogammaglobulinemia and Infection After Rituximab in Pemphigus, With Divergent Desmoglein Antibody and Immunoglobulin Kinetics: A Retrospective Cohort Study
Pemphigus is a rare autoimmune blistering disease for which rituximab is a first‐line treatment, yet most safety data derive from lymphoma and rheumatoid arthritis cohorts. This study assessed hypogammaglobulinemia and infection during rituximab treatment, the baseline predictors of new‐onset hypogammaglobulinemia, and whether desmoglein antibody titers and total immunoglobulin levels fall together. In this single‐center retrospective cohort study, the records of 97 patients given rituximab for pemphigus between January 2015 and June 2026 were reviewed. Patients who received intravenous immunoglobulin were excluded, leaving 69 patients for outcome analyses. Among 51 patients with a normal baseline immunoglobulin G level, new‐onset hypogammaglobulinemia, defined as a fall below 700 mg/dL after treatment, occurred in 5 (10%), and no patient reached the severe threshold of 400 mg/dL. Seven further patients were already below 700 mg/dL before treatment. Patients who developed new‐onset hypogammaglobulinemia were older and had lower baseline immunoglobulin G and immunoglobulin M levels (areas under the curve 0.85, 0.83, and 0.81). Patients with hypogammaglobulinemia had received more corticosteroid per cycle, so a contribution of corticosteroids cannot be excluded. Late‐onset neutropenia was not detected (0 of 69). Infection occurred in 5 of 69 patients (7%) and severe infection in 2 of 69 (3%). 6 months after induction, desmoglein 1 and desmoglein 3 antibody titers had fallen to 16% and 19% of baseline ( p < 0.001), whereas immunoglobulin G remained at 97% ( p = 0.46), independently of hypogammaglobulinemia. Hypogammaglobulinemia remained mild and the serologic response was not mirrored in total immunoglobulin levels. Advanced age and low baseline immunoglobulin levels are candidate markers of risk. These findings come from a retrospective single‐center cohort and require confirmation in larger series.
- 25 October 2026
- Published by Wiley in The Journal of Dermatology
Hypogammaglobulinemia and Infection After Rituximab in Pemphigus, With Divergent Desmoglein Antibody and Immunoglobulin Kinetics: A Retrospective Cohort Study
Pemphigus is a rare autoimmune blistering disease for which rituximab is a first‐line treatment, yet most safety data derive from lymphoma and rheumatoid arthritis cohorts. This study assessed hypogammaglobulinemia and infection during rituximab treatment, the baseline predictors of new‐onset hypogammaglobulinemia, and whether desmoglein antibody titers and total immunoglobulin levels fall together. In this single‐center retrospective cohort study, the records of 97 patients given rituximab for pemphigus between January 2015 and June 2026 were reviewed. Patients who received intravenous immunoglobulin were excluded, leaving 69 patients for outcome analyses. Among 51 patients with a normal baseline immunoglobulin G level, new‐onset hypogammaglobulinemia, defined as a fall below 700 mg/dL after treatment, occurred in 5 (10%), and no patient reached the severe threshold of 400 mg/dL. Seven further patients were already below 700 mg/dL before treatment. Patients who developed new‐onset hypogammaglobulinemia were older and had lower baseline immunoglobulin G and immunoglobulin M levels (areas under the curve 0.85, 0.83, and 0.81). Patients with hypogammaglobulinemia had received more corticosteroid per cycle, so a contribution of corticosteroids cannot be excluded. Late‐onset neutropenia was not detected (0 of 69). Infection occurred in 5 of 69 patients (7%) and severe infection in 2 of 69 (3%). 6 months after induction, desmoglein 1 and desmoglein 3 antibody titers had fallen to 16% and 19% of baseline ( p < 0.001), whereas immunoglobulin G remained at 97% ( p = 0.46), independently of hypogammaglobulinemia. Hypogammaglobulinemia remained mild and the serologic response was not mirrored in total immunoglobulin levels. Advanced age and low baseline immunoglobulin levels are candidate markers of risk. These findings come from a retrospective single‐center cohort and require confirmation in larger series.
- 8 December 2025
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 64 (4) , 713-715
Polimeraz zincir reaksiyonu ile tanı alan kutanöz layşmanyazis olgusu
Şark çıbanı (Layşmanyazis), farklı klinik görünümlerle ortaya çıkabilen parazit kaynaklı bir hastalıktır. Türkiye'de özellikle güneydoğu bölgesinde endemik olarak görülmektedir. Bu olgu sunumunda, saçlı deride yer alan plak benzeri lezyonlar nedeniyle kliniğe başvuran 67 yaşındaki bir erkek hastada, klinik olarak “çivi belirtisi” gözlenmesi üzerine kutanöz layşmanyazis ön tanısı düşünülmüş ve tanı, diğer tanısal yöntemler negatif sonuç vermesine rağmen, yalnızca polimeraz zincir reaksiyonu ile kesinleştirilmiştir. Olgu, kronik lezyonlarda klasik tanı yöntemlerinin yetersiz kalabileceğini ve Behçet’in çivi belirtisinin özgül bir klinik bulgu olarak dikkatle değerlendirilmesi gerektiğini göstermektedir. Not: Bu olgu sunumu 22-24 Mayıs 2025 tarihlerinde Prag’da düzenlenen Avrupa Dermatoloji ve Veneroloji Akademisi (EADV) Kongresi’nde e-poster olarak sunulmuştur. (Özet ID:370, e-Poster No: P0755)
- 8 December 2025
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 64 (4) , 713-715
Polimeraz zincir reaksiyonu ile tanı alan kutanöz layşmanyazis olgusu
Şark çıbanı (Layşmanyazis), farklı klinik görünümlerle ortaya çıkabilen parazit kaynaklı bir hastalıktır. Türkiye'de özellikle güneydoğu bölgesinde endemik olarak görülmektedir. Bu olgu sunumunda, saçlı deride yer alan plak benzeri lezyonlar nedeniyle kliniğe başvuran 67 yaşındaki bir erkek hastada, klinik olarak “çivi belirtisi” gözlenmesi üzerine kutanöz layşmanyazis ön tanısı düşünülmüş ve tanı, diğer tanısal yöntemler negatif sonuç vermesine rağmen, yalnızca polimeraz zincir reaksiyonu ile kesinleştirilmiştir. Olgu, kronik lezyonlarda klasik tanı yöntemlerinin yetersiz kalabileceğini ve Behçet’in çivi belirtisinin özgül bir klinik bulgu olarak dikkatle değerlendirilmesi gerektiğini göstermektedir. Not: Bu olgu sunumu 22-24 Mayıs 2025 tarihlerinde Prag’da düzenlenen Avrupa Dermatoloji ve Veneroloji Akademisi (EADV) Kongresi’nde e-poster olarak sunulmuştur. (Özet ID:370, e-Poster No: P0755)
- 2 February 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (3) , 276-280
Alterations in Retinal Vascularity in Severe Psoriasis
To evaluate the changes in retinal vascularity in patients with severe psoriasis.Patients with severe psoriasis [psoriasis area-severity index (PASI) >10] who did not get any systemic treatment in ...
- 2 February 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (3) , 276-280
Alterations in Retinal Vascularity in Severe Psoriasis
To evaluate the changes in retinal vascularity in patients with severe psoriasis.Patients with severe psoriasis [psoriasis area-severity index (PASI) >10] who did not get any systemic treatment in ...
- 4 July 2022
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 24 (1-5) , 36-39
Evaluation of platelet-rich plasma efficacy in melasma
Platelet-rich plasma (PRP), which is widely used in many dermatologic conditions, has also been used in the treatment of melasma in recent years. The objective of this study is to determine the efficacy of PRP in melasma. Fifteen female patients with melasma participated in this study. Intradermal PRP was performed every 3 weeks for three times. We photographed all participants, performed Melasma Area and Severity Index (MASI), and measured melanin and erythema index (EI) with mexameter before every session and 1 month after the last session. Patients self-assessment of pigmentation grade (0–10) were also employed at baseline and 1 month after the last procedure. Mean MASI of the patients reduced from 10 ± 3.6 to 7.3 ± 2.5. Melanin index (MI) and EI evaluated by mexameter reduced from 256.5 ± 31 to 238.9 ± 29.9 and from 329.9 ± 53.8 to 322.7 ± 77.6, respectively. Mean patients self-assessment score (PSS) reduced from 8.3 ± 1.3 to 5 ± 1.4. Mean MASI, MI, and PSS reduction after treatment was found significant (p = .001, p = .000, p = .000). Intradermal application of PRP is an effective option for treatment of melasma. It also has other benefits like improvement in skin appearance. Because recurrence is common in melasma, depigmenting agents should be used after all procedures.
- 4 July 2022
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 24 (1-5) , 36-39
Evaluation of platelet-rich plasma efficacy in melasma
Platelet-rich plasma (PRP), which is widely used in many dermatologic conditions, has also been used in the treatment of melasma in recent years. The objective of this study is to determine the efficacy of PRP in melasma. Fifteen female patients with melasma participated in this study. Intradermal PRP was performed every 3 weeks for three times. We photographed all participants, performed Melasma Area and Severity Index (MASI), and measured melanin and erythema index (EI) with mexameter before every session and 1 month after the last session. Patients self-assessment of pigmentation grade (0–10) were also employed at baseline and 1 month after the last procedure. Mean MASI of the patients reduced from 10 ± 3.6 to 7.3 ± 2.5. Melanin index (MI) and EI evaluated by mexameter reduced from 256.5 ± 31 to 238.9 ± 29.9 and from 329.9 ± 53.8 to 322.7 ± 77.6, respectively. Mean patients self-assessment score (PSS) reduced from 8.3 ± 1.3 to 5 ± 1.4. Mean MASI, MI, and PSS reduction after treatment was found significant (p = .001, p = .000, p = .000). Intradermal application of PRP is an effective option for treatment of melasma. It also has other benefits like improvement in skin appearance. Because recurrence is common in melasma, depigmenting agents should be used after all procedures.
- 15 March 2022
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 61 (1) , 58-63
Retrospective evaluation of clinical features in hospitalized herpes zoster patients
Aim: Herpes zoster is a dermatomal vesicular eruption caused by the reactivation of varicella-zoster virus (VZV) that remains latent in the dorsal root ganglia. Due to the impairment of cellular immune capacity with aging, it is commonly seen in advanced age. Approximately 3-10% of the cases need to be hospitalized. We aimed to determine the frequency of dissemination and the demographic and clinical characteristics in hospitalized herpes zoster patients in a dermatology clinic of a tertiary hospital. Materials and Methods: The records of 19 herpes zoster patients hospitalized in our clinic between June 2019 and November 2020 were retrospectively reviewed. Patients' age, gender, dermatome involved, presence of dissemination, concomitant diseases, and development of post-herpetic neuralgia were noted. Results: Disseminated herpes zoster was seen in 36.8% (no:7) of the patients. Of patients 63.2% (no:12) had ophthalmic herpes zoster. The relationship between dissemination and age, gender, presence of immunosuppression and development of post-herpetic neuralgia was not statistically significant. While no death was observed in the non-disseminated group, one patient died in the disseminated herpes zoster group. Conclusion: In this study, the mean age of the patients, the accompanying immunosuppressive state, and the rate of post-herpetic neuralgia were found to be higher in the disseminated herpes zoster group than the non-disseminated group. But it was not significant. Studies on disseminated herpes zoster which have a higher mortality are limited due to the low frequency of the disease. Studies involving larger numbers of patients are needed in order to report the clinical features and mortality rates more clearly in these patients.
- 15 March 2022
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 61 (1) , 58-63
Retrospective evaluation of clinical features in hospitalized herpes zoster patients
Aim: Herpes zoster is a dermatomal vesicular eruption caused by the reactivation of varicella-zoster virus (VZV) that remains latent in the dorsal root ganglia. Due to the impairment of cellular immune capacity with aging, it is commonly seen in advanced age. Approximately 3-10% of the cases need to be hospitalized. We aimed to determine the frequency of dissemination and the demographic and clinical characteristics in hospitalized herpes zoster patients in a dermatology clinic of a tertiary hospital. Materials and Methods: The records of 19 herpes zoster patients hospitalized in our clinic between June 2019 and November 2020 were retrospectively reviewed. Patients' age, gender, dermatome involved, presence of dissemination, concomitant diseases, and development of post-herpetic neuralgia were noted. Results: Disseminated herpes zoster was seen in 36.8% (no:7) of the patients. Of patients 63.2% (no:12) had ophthalmic herpes zoster. The relationship between dissemination and age, gender, presence of immunosuppression and development of post-herpetic neuralgia was not statistically significant. While no death was observed in the non-disseminated group, one patient died in the disseminated herpes zoster group. Conclusion: In this study, the mean age of the patients, the accompanying immunosuppressive state, and the rate of post-herpetic neuralgia were found to be higher in the disseminated herpes zoster group than the non-disseminated group. But it was not significant. Studies on disseminated herpes zoster which have a higher mortality are limited due to the low frequency of the disease. Studies involving larger numbers of patients are needed in order to report the clinical features and mortality rates more clearly in these patients.
- 30 June 2021
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 60 (2) , 155-162
The prevalence and risk factors of hand eczema among emergency healthcare workers during the COVID-19 pandemic
Aim: The preventive measures to decelerate the spread of the novel coronavirus include intense hand sanitizing which is a risk factor for hand eczema. Occupational hand eczema is common among healthcare workers due to their exposure to wet work and chemical irritants. We aimed to evaluate the prevalence of hand eczema among healthcare workers currently working in the emergency department and investigate the alterations regarding the risk factors during the COVID-19 pandemic that began in March 2020 in Turkey. Materials and Methods: An online survey was sent to healthcare workers in emergency departments all over Turkey. Participants were asked to evaluate their frequency of hand washing, hand eczema, glove use and moisturizer use as prior to and during the COVID-19 pandemic. Hand eczema and associated symptoms were self-reported. Results: Three hundred fifty-four healthcare workers, consisting of 260 emergency physicians and 94 nurses returned the survey. The prevalence of HE among 354 participants with a median age of 32 was 48.6% (n=161). HE was associated with having an atopic history (p<0.001). 54.8% (n=194) of the participants reported having symptoms associated with HE prior to the pandemic and the rate increased significantly to 64.7% (n=229) during the pandemic (p<0.001). The exposure to the risk factors of hand eczema such as hand washing frequency and duration of glove use showed a relevant increase during the pandemic (p<0.001). As well as moisturizer applying frequency which also increased during the pandemic (p<0.001). Conclusion: With the outbreak of the COVID-19 pandemic, Healthcare workers intensified their hand hygiene practices as recommended and increased their risk for hand eczema.
- 30 June 2021
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 60 (2) , 155-162
The prevalence and risk factors of hand eczema among emergency healthcare workers during the COVID-19 pandemic
Aim: The preventive measures to decelerate the spread of the novel coronavirus include intense hand sanitizing which is a risk factor for hand eczema. Occupational hand eczema is common among healthcare workers due to their exposure to wet work and chemical irritants. We aimed to evaluate the prevalence of hand eczema among healthcare workers currently working in the emergency department and investigate the alterations regarding the risk factors during the COVID-19 pandemic that began in March 2020 in Turkey. Materials and Methods: An online survey was sent to healthcare workers in emergency departments all over Turkey. Participants were asked to evaluate their frequency of hand washing, hand eczema, glove use and moisturizer use as prior to and during the COVID-19 pandemic. Hand eczema and associated symptoms were self-reported. Results: Three hundred fifty-four healthcare workers, consisting of 260 emergency physicians and 94 nurses returned the survey. The prevalence of HE among 354 participants with a median age of 32 was 48.6% (n=161). HE was associated with having an atopic history (p<0.001). 54.8% (n=194) of the participants reported having symptoms associated with HE prior to the pandemic and the rate increased significantly to 64.7% (n=229) during the pandemic (p<0.001). The exposure to the risk factors of hand eczema such as hand washing frequency and duration of glove use showed a relevant increase during the pandemic (p<0.001). As well as moisturizer applying frequency which also increased during the pandemic (p<0.001). Conclusion: With the outbreak of the COVID-19 pandemic, Healthcare workers intensified their hand hygiene practices as recommended and increased their risk for hand eczema.
- 4 September 2020
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 44 (3) , 164-167
Comparison of Skin Scraping and Standard Superficial Skin Biopsy in the Laboratory Diagnosis of Scabies
Scabies is diagnosed based on the presence of burrows on the skin, Sarcoptes scabiei adult, egg, or scybala in skin scrapings. The laboratory diagnosis of scabies poses various challenges. We aimed to compare the analytical performance of skin scraping and standard superficial skin biopsy (SSSB) and to investigate the correlation with false negative results in the laboratory diagnosis of scabies. Skin scraping and SSSB were applied from July 1 to December 31, 2018 on 42 patients whose burrows were marked using dermatoscopy, as obtained from the laboratory information system. The number of patients who tested positive for scabies with skin scraping was 18 (42.9%) and 24 (57.1%) with SSSB, and the difference was significant (p=0.003). Sensitivity was 42.9% for skin scraping and 57.1% for SSSB. The number of positive cases with both techniques was 15 (35.7%). The number of patients positive with only skin scraping was 3 (7.1%) and only SSSB was 9 (21.4%). To date, it has seemed impossible to diagnose scabies using a single clinical or laboratory test. According to our results, SSSB is an inexpensive and easy-to-apply method with high sensitivity for obtaining skin samples for scabies laboratory diagnosis.
- 4 September 2020
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 44 (3) , 164-167
Comparison of Skin Scraping and Standard Superficial Skin Biopsy in the Laboratory Diagnosis of Scabies
Scabies is diagnosed based on the presence of burrows on the skin, Sarcoptes scabiei adult, egg, or scybala in skin scrapings. The laboratory diagnosis of scabies poses various challenges. We aimed to compare the analytical performance of skin scraping and standard superficial skin biopsy (SSSB) and to investigate the correlation with false negative results in the laboratory diagnosis of scabies. Skin scraping and SSSB were applied from July 1 to December 31, 2018 on 42 patients whose burrows were marked using dermatoscopy, as obtained from the laboratory information system. The number of patients who tested positive for scabies with skin scraping was 18 (42.9%) and 24 (57.1%) with SSSB, and the difference was significant (p=0.003). Sensitivity was 42.9% for skin scraping and 57.1% for SSSB. The number of positive cases with both techniques was 15 (35.7%). The number of patients positive with only skin scraping was 3 (7.1%) and only SSSB was 9 (21.4%). To date, it has seemed impossible to diagnose scabies using a single clinical or laboratory test. According to our results, SSSB is an inexpensive and easy-to-apply method with high sensitivity for obtaining skin samples for scabies laboratory diagnosis.
- 2 July 2020
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 39 (3) , 249-253
Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience
Purpose: Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6 weeks. Omalizumab, an anti-IgE antibody that binds circulating free IgE, has recently emerged as a promising treatment for CSU, a condition which impairs patients’ quality of life. We aimed to contribute real life data by reporting our experience with omalizumab in the treatment of intractable CSU. Methods: Of 140 patients treated with omalizumab in our clinic between September 2013 and January 2018, 86 CSU patients with available current data were retrospectively evaluated in terms of sex, age, urticaria duration, urticaria activity score over 7 days (UAS7) before and after omalizumab, relapses and time to relapse, length of remission after omalizumab cessation, adverse events, and comorbidities. Results: The mean age of the patients was 45.5 ± 14.3 years and 73.3% were women. Mean duration of urticaria before initiation of omalizumab therapy was 54.5 ± 67 months. All patients had used antihistamines before starting omalizumab treatment. The mean number of omalizumab doses was 11.9 ± 9.3. The mean duration of omalizumab treatment was 13.3 ± 10.4 months. Mean UAS7 score was 38.9 ± 4.1 before the start of omalizumab treatment, and 7.9 ± 10.5 after treatment. Treatment was discontinued in 10 patients (11.6%) due to nonresponse or loss of effect. Four patients (4.65%) experienced adverse events. Treatment was discontinued in 1 patient (1.16%) due to side effects. Of the 55 patients whose treatment was discontinued after their symptoms resolved, 31 (56.3%) relapsed after omalizumab cessation. Twenty-four patients (43.6%) did not relapse after omalizumab cessation. Conclusions: Our results show that omalizumab was an effective treatment for intractable CSU and did not cause any serious adverse effects other than asthenia, vertigo, and injection site reaction in 4 patients. These findings are relevant because they reflect real-life data.
- 2 July 2020
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 39 (3) , 249-253
Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience
Purpose: Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6 weeks. Omalizumab, an anti-IgE antibody that binds circulating free IgE, has recently emerged as a promising treatment for CSU, a condition which impairs patients’ quality of life. We aimed to contribute real life data by reporting our experience with omalizumab in the treatment of intractable CSU. Methods: Of 140 patients treated with omalizumab in our clinic between September 2013 and January 2018, 86 CSU patients with available current data were retrospectively evaluated in terms of sex, age, urticaria duration, urticaria activity score over 7 days (UAS7) before and after omalizumab, relapses and time to relapse, length of remission after omalizumab cessation, adverse events, and comorbidities. Results: The mean age of the patients was 45.5 ± 14.3 years and 73.3% were women. Mean duration of urticaria before initiation of omalizumab therapy was 54.5 ± 67 months. All patients had used antihistamines before starting omalizumab treatment. The mean number of omalizumab doses was 11.9 ± 9.3. The mean duration of omalizumab treatment was 13.3 ± 10.4 months. Mean UAS7 score was 38.9 ± 4.1 before the start of omalizumab treatment, and 7.9 ± 10.5 after treatment. Treatment was discontinued in 10 patients (11.6%) due to nonresponse or loss of effect. Four patients (4.65%) experienced adverse events. Treatment was discontinued in 1 patient (1.16%) due to side effects. Of the 55 patients whose treatment was discontinued after their symptoms resolved, 31 (56.3%) relapsed after omalizumab cessation. Twenty-four patients (43.6%) did not relapse after omalizumab cessation. Conclusions: Our results show that omalizumab was an effective treatment for intractable CSU and did not cause any serious adverse effects other than asthenia, vertigo, and injection site reaction in 4 patients. These findings are relevant because they reflect real-life data.
- Open Access
- 13 March 2020
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 59 (1) , 67-70
Nodule development after nasolabial filling: A case report
Tr en Dolgular, yüzeyel kırışıkların görünümünü azaltmak, yüzün derin kırışıklık ve kıvrımlarını yumuşatmanın yanı sıra atrofik skar, dudak büyütme, lipoatrofi veya yaşlanmaya bağlı yağ kaybedilen bölgelere hacim kazandırmak amacıyla uygulanabilmektedir. Dermal dolgu uygulaması sonrası gecikmiş nodül gelişimi hipersensitivite reaksiyonu, biyofilm gelişimi, yumuşak doku enfeksiyonu veya yabancı cisim granülomu gelişimine bağlı görülebilir ve kalıcı dolgu uygulamalarında geçici dolguya göre daha sık görülürler. Burada kalıcı dermal dolgu uygulaması sonrası fluktuasyon gösteren geç nodül gelişimi olan ve altı hafta doksisiklin ve siprofloksasin kullanımından sonra iki kez lezyon içine kortikosteroid uygulaması ve kolşisin tedavisiyle kontrol altına alınan bir olgu, dermal dolgu uygulamalarının komplikasyonlarına dikkat çekmek amacıyla sunulmaktadır. Fillers can be applied to reduce the appearance of superficial wrinkles, to soften the deep wrinkles and curves of the face, as well as to provide volume to atrophic scar, lip augmentation, lipoatrophy or fat loss areas due to aging. Delayed nodule development after dermal filler application may be seen due to hypersensitivity reaction, biofilm development, soft tissue infection or foreign body granuloma development and is more common by permanent filler applications. Here, a case with nasolabial delayed nodule development following permanent dermal filler application and controlled by intralesional corticosteroid application and colchicine treatment after the use of doxycycline and ciprofloxacin for 6 weeks to draw attention to the complications of dermal filler applications.
- 13 March 2020
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 59 (1) , 67-70
Open AccessNodule development after nasolabial filling: A case report
Tr en Dolgular, yüzeyel kırışıkların görünümünü azaltmak, yüzün derin kırışıklık ve kıvrımlarını yumuşatmanın yanı sıra atrofik skar, dudak büyütme, lipoatrofi veya yaşlanmaya bağlı yağ kaybedilen bölgelere hacim kazandırmak amacıyla uygulanabilmektedir. Dermal dolgu uygulaması sonrası gecikmiş nodül gelişimi hipersensitivite reaksiyonu, biyofilm gelişimi, yumuşak doku enfeksiyonu veya yabancı cisim granülomu gelişimine bağlı görülebilir ve kalıcı dolgu uygulamalarında geçici dolguya göre daha sık görülürler. Burada kalıcı dermal dolgu uygulaması sonrası fluktuasyon gösteren geç nodül gelişimi olan ve altı hafta doksisiklin ve siprofloksasin kullanımından sonra iki kez lezyon içine kortikosteroid uygulaması ve kolşisin tedavisiyle kontrol altına alınan bir olgu, dermal dolgu uygulamalarının komplikasyonlarına dikkat çekmek amacıyla sunulmaktadır. Fillers can be applied to reduce the appearance of superficial wrinkles, to soften the deep wrinkles and curves of the face, as well as to provide volume to atrophic scar, lip augmentation, lipoatrophy or fat loss areas due to aging. Delayed nodule development after dermal filler application may be seen due to hypersensitivity reaction, biofilm development, soft tissue infection or foreign body granuloma development and is more common by permanent filler applications. Here, a case with nasolabial delayed nodule development following permanent dermal filler application and controlled by intralesional corticosteroid application and colchicine treatment after the use of doxycycline and ciprofloxacin for 6 weeks to draw attention to the complications of dermal filler applications.
- 9 September 2019
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 21 (7-8) , 378-381
Efficacy of intense pulsed light therapy for melasma
(2019). Efficacy of intense pulsed light therapy for melasma. Journal of Cosmetic and Laser Therapy. Ahead of Print.
- 9 September 2019
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 21 (7-8) , 378-381
Efficacy of intense pulsed light therapy for melasma
(2019). Efficacy of intense pulsed light therapy for melasma. Journal of Cosmetic and Laser Therapy. Ahead of Print.